Pharmaceutical Third-Party Logistics Market Size & Growth Forecast 2027–2036, By Segments (Temperature, Service, Product, Therapeutic Area, Manufacturer Size), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Pharmaceutical Third-Party Logistics Market size was over USD 161.8 billion in 2026 and is likely to grow at a 8.46% CAGR between 2027 and 2036, reaching USD 364.48 billion by 2036. The industry revenue for 2027 is calculated at USD 173.32 billion.
Get more details on this report
Request Free Sample ReportPharmaceutical Third-Party Logistics Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for a 40.60% share in 2026, driven by advanced supply chains, outsourcing adoption, and demand for specialized logistics services.
- Asia Pacific is projected to expand at a 10.28% CAGR, fueled by pharmaceutical growth, outsourced logistics demand, and expanding distribution networks.
Segment Momentum
- Ambient accounted for 50.88% of the market in 2026 because many pharmaceuticals can be stored and transported without cold-chain infrastructure, enabling efficient, high-volume distribution with lower operational complexity.
- DSCSA and Serialization Services are the fastest-growing segment as pharmaceutical companies increasingly require advanced traceability, product verification, and compliance-focused data management across distribution networks.
Market Expansion Drivers
- Growing demand for temperature-sensitive biologics accelerating cold chain logistics investments.
- Increasing pharmaceutical outsourcing strategies driving reliance on specialized 3PL service providers.
- Integration of AI-enabled monitoring and predictive analytics improving pharmaceutical supply chain efficiency.
Leading Market Participants
- Major companies in the pharmaceutical third-party logistics market include Cencora Corporation (United States), McKesson Corporation (United States), Cardinal Health, Inc. (United States), Kuehne + Nagel International AG (Switzerland), DB Schenker (Germany), CEVA Logistics AG (Switzerland), Thermo Fisher Scientific Inc. (United States), EVERSANA Company (United States), Kerry Logistics Network Limited (Hong Kong), Knipper Health, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 161.8 billion
- 2027 Estimated Market Size: USD 173.32 billion.
- Projected Market Size: USD 364.48 billion by 2036
- Growth Forecast: 8.46% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Ambient (Temperature) | Storage and Shipping (Service) | Branded (Product) | Oncology (Therapeutic Area) | Large (Manufacturer Size)
- Emerging Opportunity Segment: Refrigerated (Temperature) | DSCSA and Serialization Services (Service) | Cell Therapy (Product) | Neurology (Therapeutic Area) | Medium (Manufacturer Size)
Market Growth Drivers and Industry Trends
Growing demand for temperature-sensitive biologics accelerating cold chain logistics investments
The pharmaceutical third-party logistics market growth is being supported by the expanding use of biologics and other temperature-sensitive therapies that require tightly controlled storage and transportation conditions. These products demand specialized refrigeration, validated packaging, temperature monitoring, and carefully coordinated distribution networks to preserve product integrity throughout the supply chain. As pharmaceutical portfolios become more dependent on therapies with stringent handling requirements, manufacturers increasingly require logistics partners with dedicated cold chain capabilities, controlled facilities, and compliance-oriented operating processes.
Increasing pharmaceutical outsourcing strategies driving reliance on specialized 3PL service providers
Pharmaceutical manufacturers are increasingly outsourcing logistics activities to specialized providers, which will drive the pharmaceutical third-party logistics market growth by allowing companies to focus internal resources on research, manufacturing, and commercialization. External logistics specialists can manage warehousing, transportation, inventory coordination, regulatory documentation, and distribution across complex pharmaceutical networks. Greater reliance on outsourced logistics also enables manufacturers to access established infrastructure and specialized handling capabilities without maintaining equivalent operational resources internally, particularly when distribution requirements span multiple regions.
Integration of AI-enabled monitoring and predictive analytics improving pharmaceutical supply chain efficiency
Integration of advanced digital technologies is reshaping pharmaceutical logistics, with AI-enabled monitoring helping the pharmaceutical third-party logistics market growth through greater visibility and more responsive supply chain management. Predictive analytics can support shipment tracking, demand forecasting, inventory planning, route optimization, and early identification of potential temperature or delivery disruptions. These capabilities allow logistics providers to use operational data more effectively, coordinate pharmaceutical movements with greater precision, and respond more quickly to exceptions across increasingly complex distribution networks.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Growing demand for temperature-sensitive biologics accelerating cold chain logistics investments | 2.00% | High | North America, Asia Pacific | High | Near Term |
| Increasing pharmaceutical outsourcing strategies driving reliance on specialized 3PL service providers | 1.70% | Moderate | Europe, North America | High | Mid Term |
| Integration of AI-enabled monitoring and predictive analytics improving pharmaceutical supply chain efficiency | 1.40% | High | Asia Pacific, North America | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of 40.60% in 2026 in the pharmaceutical third-party logistics market, supported by a sophisticated pharmaceutical supply chain, extensive healthcare infrastructure, and strong demand for specialized distribution services. The need for temperature-controlled transportation, regulatory compliance, inventory visibility, and secure handling of sensitive pharmaceutical products is encouraging manufacturers and healthcare providers to rely on specialized logistics capabilities. Mature distribution networks and increasing complexity in pharmaceutical supply chains further strengthen the region’s position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is experiencing rapid development as pharmaceutical manufacturing capacity expands and healthcare systems become more integrated with modern logistics networks. Increasing demand for reliable drug distribution, greater adoption of temperature-controlled logistics, and improvements in transportation and warehousing infrastructure are supporting market expansion. Growing pharmaceutical production and rising healthcare consumption across emerging economies are also creating greater need for specialized third-party logistics services capable of maintaining product quality throughout distribution.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants/Startups i Scale Low Medium High | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Supply NetworksGermany emphasizes pharmaceutical logistics solutions that ensure product integrity, traceability, and efficient cross-border distribution. The country's advanced healthcare manufacturing ecosystem supports investment in highly controlled logistics operations.
France 🇫🇷
Regulated Distribution ExcellenceFrance relies on specialized pharmaceutical logistics providers to maintain regulatory compliance, secure transportation, and product integrity across healthcare supply chains. The market continues emphasizing traceable logistics solutions for temperature-sensitive medicines.
Italy 🇮🇹
Healthcare Supply CoordinationItaly enhances pharmaceutical third-party logistics through improved warehousing, distribution efficiency, and cold chain management supporting hospitals and pharmacies. Italian logistics providers increasingly focus on dependable nationwide delivery for sensitive pharmaceutical products.
Japan 🇯🇵
Reliable Cold Chain OperationsJapan prioritizes pharmaceutical third-party logistics services that maintain strict temperature control and timely delivery for sensitive healthcare products. Japanese logistics providers continue strengthening operational reliability through automation and quality assurance practices.
South Korea 🇰🇷
Biopharma Logistics ExpansionSouth Korea strengthens pharmaceutical third-party logistics capabilities to support expanding biopharmaceutical manufacturing and healthcare distribution requirements. Investment in cold chain infrastructure and digital tracking enhances supply chain efficiency throughout the country.
United States 🇺🇸
Integrated Healthcare DistributionThe U.S. pharmaceutical third-party logistics market focuses on temperature-controlled distribution, inventory visibility, and regulatory compliance across complex healthcare supply chains. Logistics providers continue expanding specialized services that support biologics and specialty pharmaceuticals.
Segment Leadership and Growth Trends
Pharmaceutical Third-Party Logistics Market Share (%), by Temperature, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTemperature Segment Analysis: Ambient (Largest Segment) vs Refrigerated (Fastest-Growing Segment)
The ambient segment accounted for the largest share of the pharmaceutical third-party logistics market in 2026, reflecting the broad range of pharmaceutical products that can be transported and stored under controlled room-temperature conditions. Ambient logistics generally offers wider distribution flexibility and simpler handling requirements than temperature-sensitive alternatives, supporting extensive use across pharmaceutical supply chains. Increasing outsourcing of warehousing, transportation, and distribution activities also enables pharmaceutical manufacturers to access specialized logistics capabilities while maintaining reliable product movement across markets.
Refrigerated logistics is the fastest-growing segment, driven by the increasing need to maintain controlled temperatures for products that are sensitive to thermal variation. The expansion of temperature-sensitive therapies, biologics, and other specialized pharmaceutical products is increasing demand for validated cold-chain transportation and storage. Greater emphasis on product integrity throughout distribution is encouraging logistics providers to strengthen temperature monitoring, handling procedures, and specialized infrastructure, supporting continued growth of refrigerated services.
Service Segment Analysis: Storage and Shipping (Largest Segment) vs DSCSA and Serialization Services (Fastest-Growing Segment)
In 2026, storage and shipping represented the largest segment of the pharmaceutical third-party logistics market, reflecting the fundamental role of warehousing and transportation in pharmaceutical distribution. These services support inventory management, order fulfillment, product handling, and movement between manufacturers, distributors, healthcare providers, and other supply-chain participants. Rising pharmaceutical production and increasingly complex distribution networks are encouraging manufacturers to outsource logistics activities to providers capable of maintaining product quality, regulatory compliance, and reliable delivery.
DSCSA and serialization services are experiencing the fastest growth as pharmaceutical supply chains place greater emphasis on product traceability, authentication, and regulatory compliance. Serialization enables individual products and packaging units to be identified and tracked through distribution channels, strengthening visibility and helping address risks associated with counterfeit or diverted medicines. As regulatory requirements and supply-chain transparency expectations increase, demand for specialized data management, verification, and traceability capabilities is supporting expansion of this service segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Temperature | Ambient, Refrigerated, Frozen, Ultra-frozen/Deep-Frozen, Cryogenic | Ambient | Refrigerated |
| Service | Storage and Shipping, Order-to-cash, Title Model, DSCSA and Serialization Services, Pharmaceutical Sampling, Others | Storage and Shipping | DSCSA and Serialization Services |
| Product | Branded, Generic, Biosimilar, Vaccine, Cell Therapy, Gene Therapy, Others | Branded | Cell Therapy |
| Therapeutic Area | Oncology, Cardiovascular Diseases, Infectious Diseases, Neurology, Diabetes, Nephrology, Rheumatology, Allergy/Asthma, Gastroenterology, Ophthalmology, Others | Oncology | Neurology |
| Manufacturer Size | Large, Medium, Small | Large | Medium |
Competitive Landscape and Market Positioning
Top players in the pharmaceutical third-party logistics market:
1. Cencora Corporation (United States)
2. McKesson Corporation (United States)
3. Cardinal Health Inc. (United States)
4. Kuehne + Nagel International AG (Switzerland)
5. DB Schenker (Germany)
6. CEVA Logistics AG (Switzerland)
7. Thermo Fisher Scientific Inc. (United States)
8. EVERSANA Company (United States)
9. Kerry Logistics Network Limited (Hong Kong)
10. Knipper Health Inc. (United States)
The pharmaceutical third-party logistics market is being transformed through the integration of temperature-controlled supply chains, real-time tracking systems, and automated inventory management technologies. Service providers are emphasizing regulatory compliance and efficient distribution frameworks to support the safe handling of sensitive pharmaceutical products. Growing complexity in global healthcare logistics is further accelerating digital transformation within the market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Cencora Corporation (United States) | |||||||
| McKesson Corporation (United States) | |||||||
| Cardinal Health Inc. (United States) | |||||||
| Kuehne + Nagel International AG (Switzerland) | |||||||
| DB Schenker (Germany) | |||||||
| CEVA Logistics AG (Switzerland) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| EVERSANA Company (United States) | |||||||
| Kerry Logistics Network Limited (Hong Kong) | |||||||
| Knipper Health Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| EVERSANA | Apr-25 | EVERSANA expanded its distribution footprint with a new 358,000-square-foot facility in Memphis. The site incorporates cold-chain capabilities and AI-driven automation to enhance temperature-controlled logistics, supply chain efficiency, and advanced operational handling for complex pharmaceutical products. |
| DHL Group | Apr-25 | DHL Group acquired Cryopdp, a provider specialized in temperature-controlled logistics for biopharmaceuticals and clinical trials. This acquisition bolsters DHL’s specialized service offerings, strengthening its ability to manage high-stakes, time-sensitive shipments within the life sciences and healthcare vertical. |
| DHL Group | Mar-25 | DHL Group announced a strategic initiative to double its Life Science and Healthcare revenue to approximately EUR 10 billion by 2030. The growth plan involves substantial investment in expanding its network of GDP-compliant facilities globally to meet rising demand for specialized pharmaceutical distribution services. |
| UPS | Jan-25 | UPS completed the acquisition of Frigo-Trans and BPL to enhance its temperature-controlled logistics capabilities in Europe. These additions strengthen UPS's infrastructure for handling sensitive healthcare products, providing increased capacity and specialized expertise to support its regional pharmaceutical supply chain operations. |
| DHL Supply Chain | Jan-25 | DHL Supply Chain signed an agreement to acquire Inmar Supply Chain Solutions. This acquisition significantly scales DHL's pharmaceutical 3PL presence in North America, integrating Inmar’s logistics footprint to improve service coverage and operational capacity for healthcare customers. |
| DSV | Sep-24 | DSV signed a definitive agreement to acquire DB Schenker for approximately EUR 14.3 billion. This transformative acquisition, completed in April 2025, integrates DB Schenker’s global logistics network and infrastructure into DSV, significantly scaling the company's contract logistics capabilities and market reach. |
| CEVA Logistics | Sep-24 | CEVA Logistics finalized an agreement to assume freight management responsibilities from CMA CGM. This operational realignment is designed to optimize business growth for CEVA while allowing CMA CGM to refocus on its core shipping operations, streamlining the service delivery model for clients. |
| EVERSANA | May-23 | EVERSANA extended its strategic partnership with Yaral Pharma to support the commercialization of the latter's pain and endocrinology portfolio in the U.S. The scope of the engagement includes comprehensive 3PL and operational support, facilitating seamless market access and distribution for Yaral Pharma's product line. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Pharmaceutical Third-Party Logistics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Mode of Transport | Road, Air, Sea, Rail, Multimodal Transport |
| Logistics Operating Model | Dedicated 3PL, Shared 3PL, 4PL & Lead Logistics, Integrated Logistics |
| Shipment / Delivery Destination | Manufacturer-to-Distributor, Manufacturer-to-Healthcare Provider, Manufacturer-to-Pharmacy, Direct-to-Patient |
Pharmaceutical Third-Party Logistics Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Cold Chain Infrastructure Readiness Assessment |
|
| Pharmaceutical Logistics Compliance Analysis |
|
| Specialty Drug Distribution Opportunity Assessment |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current revenue of the pharmaceutical third-party logistics market?
How is the pharmaceutical third-party logistics industry size expected to evolve during the forecast period?
How are biologics driving investment priorities in pharmaceutical third-party logistics?
How is pharmaceutical outsourcing reshaping reliance on 3PL providers?
Why is Ambient the leading temperature segment in the pharmaceutical third-party logistics market?
Which service segment is expanding the fastest in the pharmaceutical third-party logistics market?
What factors support North America’s leadership in pharmaceutical third-party logistics?
Why is Asia Pacific becoming a key growth region for pharmaceutical third-party logistics?
Which companies are driving growth in the pharmaceutical third-party logistics landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization